Skip to main content
Top
Published in: BMC Cancer 1/2013

Open Access 01-12-2013 | Research article

Reproductive factors and risk of hormone receptor positive and negative breast cancer: a cohort study

Authors: Rebecca Ritte, Kaja Tikk, Annekatrin Lukanova, Anne Tjønneland, Anja Olsen, Kim Overvad, Laure Dossus, Agnès Fournier, Françoise Clavel-Chapelon, Verena Grote, Heiner Boeing, Krasimira Aleksandrova, Antonia Trichopoulou, Pagona Lagiou, Dimitrios Trichopoulos, Domenico Palli, Franco Berrino, Amalia Mattiello, Rosario Tumino, Carlotta Sacerdote, José Ramón Quirós, Genevieve Buckland, Esther Molina-Montes, María-Dolores Chirlaque, Eva Ardanaz, Pilar Amiano, H Bas Bueno-de-Mesquita, Carla H van Gils, Petra HM Peeters, Nick Wareham, Kay-Tee Khaw, Timothy J Key, Ruth C Travis, Elisabete Weiderpass, Vanessa Dumeaux, Eliv Lund, Malin Sund, Anne Andersson, Isabelle Romieu, Sabina Rinaldi, Paulo Vineis, Melissa A Merritt, Elio Riboli, Rudolf Kaaks

Published in: BMC Cancer | Issue 1/2013

Login to get access

Abstract

Background

The association of reproductive factors with hormone receptor (HR)-negative breast tumors remains uncertain.

Methods

Within the EPIC cohort, Cox proportional hazards models were used to describe the relationships of reproductive factors (menarcheal age, time between menarche and first pregnancy, parity, number of children, age at first and last pregnancies, time since last full-term childbirth, breastfeeding, age at menopause, ever having an abortion and use of oral contraceptives [OC]) with risk of ER-PR- (n = 998) and ER+PR+ (n = 3,567) breast tumors.

Results

A later first full-term childbirth was associated with increased risk of ER+PR+ tumors but not with risk of ER-PR- tumors (≥35 vs. ≤19 years HR: 1.47 [95% CI 1.15-1.88] p trend < 0.001 for ER+PR+ tumors; ≥35 vs. ≤19 years HR: 0.93 [95% CI 0.53-1.65] p trend = 0.96 for ER-PR- tumors; P het = 0.03). The risk associations of menarcheal age, and time period between menarche and first full-term childbirth with ER-PR-tumors were in the similar direction with risk of ER+PR+ tumors (phet = 0.50), although weaker in magnitude and statistically only borderline significant. Other parity related factors such as ever a full-term birth, number of births, age- and time since last birth were associated only with ER+PR+ malignancies, however no statistical heterogeneity between breast cancer subtypes was observed. Breastfeeding and OC use were generally not associated with breast cancer subtype risk.

Conclusion

Our study provides possible evidence that age at menarche, and time between menarche and first full-term childbirth may be associated with the etiology of both HR-negative and HR-positive malignancies, although the associations with HR-negative breast cancer were only borderline significant.
Appendix
Available only for authorised users
Literature
1.
go back to reference Weigelt B, Reis-Filho JS: Histological and molecular types of breast cancer: is there a unifying taxonomy?. Nat Rev Clin Oncol. 2009, 6 (12): 718-730. 10.1038/nrclinonc.2009.166.CrossRefPubMed Weigelt B, Reis-Filho JS: Histological and molecular types of breast cancer: is there a unifying taxonomy?. Nat Rev Clin Oncol. 2009, 6 (12): 718-730. 10.1038/nrclinonc.2009.166.CrossRefPubMed
2.
go back to reference Althuis MD, Fergenbaum JH, Garcia-Closas M, Brinton LA, Madigan MP, Sherman ME: Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiol Biomarkers Prev. 2004, 13 (10): 1558-1568.PubMed Althuis MD, Fergenbaum JH, Garcia-Closas M, Brinton LA, Madigan MP, Sherman ME: Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiol Biomarkers Prev. 2004, 13 (10): 1558-1568.PubMed
3.
go back to reference Ma H, Bernstein L, Pike MC, Ursin G: Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies. Breast Cancer Res. 2006, 8 (4): R43-10.1186/bcr1525.CrossRefPubMedPubMedCentral Ma H, Bernstein L, Pike MC, Ursin G: Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies. Breast Cancer Res. 2006, 8 (4): R43-10.1186/bcr1525.CrossRefPubMedPubMedCentral
4.
go back to reference Rakha EA, El-Sayed ME, Green AR, Paish EC, Powe DG, Gee J, Nicholson RI, Lee AH, Robertson JF, Ellis IO: Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. J Clin Oncol. 2007, 25 (30): 4772-4778. 10.1200/JCO.2007.12.2747.CrossRefPubMed Rakha EA, El-Sayed ME, Green AR, Paish EC, Powe DG, Gee J, Nicholson RI, Lee AH, Robertson JF, Ellis IO: Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. J Clin Oncol. 2007, 25 (30): 4772-4778. 10.1200/JCO.2007.12.2747.CrossRefPubMed
5.
go back to reference Geyer FC, Reis-Filho JS: Microarray-base gene expression profiling as a clinical tool for breast cancer management: Are we there yet?. Int J Surg Pathol. 2008, 17 (4): 285-302.CrossRef Geyer FC, Reis-Filho JS: Microarray-base gene expression profiling as a clinical tool for breast cancer management: Are we there yet?. Int J Surg Pathol. 2008, 17 (4): 285-302.CrossRef
6.
go back to reference Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B, Desmedt C, Ignatiadis M, Sengstag T, Schutz F, Goldstein DR, Piccart M, Delorenzi M: Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res. 2008, 10 (4): R65-10.1186/bcr2124.CrossRefPubMedPubMedCentral Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B, Desmedt C, Ignatiadis M, Sengstag T, Schutz F, Goldstein DR, Piccart M, Delorenzi M: Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res. 2008, 10 (4): R65-10.1186/bcr2124.CrossRefPubMedPubMedCentral
7.
go back to reference Perou CM, Sorlie T, Eisen MB, de RM V, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D: Molecular portraits of human breast tumours. Nature. 2000, 406 (6797): 747-752. 10.1038/35021093.CrossRefPubMed Perou CM, Sorlie T, Eisen MB, de RM V, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D: Molecular portraits of human breast tumours. Nature. 2000, 406 (6797): 747-752. 10.1038/35021093.CrossRefPubMed
8.
go back to reference Tamimi RM, Baer HJ, Marotti J, Galan M, Galaburda L, Fu Y, Deitz AC, Connolly JL, Schnitt SJ, Colditz GA, Collins LC: Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer. Breast Cancer Res. 2008, 10 (4): R67-10.1186/bcr2128.CrossRefPubMedPubMedCentral Tamimi RM, Baer HJ, Marotti J, Galan M, Galaburda L, Fu Y, Deitz AC, Connolly JL, Schnitt SJ, Colditz GA, Collins LC: Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer. Breast Cancer Res. 2008, 10 (4): R67-10.1186/bcr2128.CrossRefPubMedPubMedCentral
9.
go back to reference Lord SJ, Bernstein L, Johnson KA, Malone KE, McDonald JA, Marchbanks PA, Simon MS, Strom BL, Press MF, Folger SG, Burkman RT, Deapen D, Spirtas R, Ursin G: Breast cancer risk and hormone receptor status in older women by parity, age of first birth, and breastfeeding: a case–control study. Cancer Epidemiol Biomarkers Prev. 2008, 17 (7): 1723-1730. 10.1158/1055-9965.EPI-07-2824.CrossRefPubMedPubMedCentral Lord SJ, Bernstein L, Johnson KA, Malone KE, McDonald JA, Marchbanks PA, Simon MS, Strom BL, Press MF, Folger SG, Burkman RT, Deapen D, Spirtas R, Ursin G: Breast cancer risk and hormone receptor status in older women by parity, age of first birth, and breastfeeding: a case–control study. Cancer Epidemiol Biomarkers Prev. 2008, 17 (7): 1723-1730. 10.1158/1055-9965.EPI-07-2824.CrossRefPubMedPubMedCentral
10.
go back to reference Yang XR, Chang-Claude J, Goode EL, Couch FJ, Nevanlinna H, Milne RL, Gaudet M, Schmidt MK, Broeks A, Cox A, Fasching PA, Hein R, Spurdle AB, Blows F, Driver K, Flesch-Janys D, Heinz J, Sinn P, Vrieling A, Heikkinen T, Aittomaki K, Heikkila P, Blomqvist C, Lissowska J, Peplonska B, Chanock S, Figueroa J, Brinton L, Hall P, Czene K, et al: Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst. 2011, 103 (3): 250-263. 10.1093/jnci/djq526.CrossRefPubMed Yang XR, Chang-Claude J, Goode EL, Couch FJ, Nevanlinna H, Milne RL, Gaudet M, Schmidt MK, Broeks A, Cox A, Fasching PA, Hein R, Spurdle AB, Blows F, Driver K, Flesch-Janys D, Heinz J, Sinn P, Vrieling A, Heikkinen T, Aittomaki K, Heikkila P, Blomqvist C, Lissowska J, Peplonska B, Chanock S, Figueroa J, Brinton L, Hall P, Czene K, et al: Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst. 2011, 103 (3): 250-263. 10.1093/jnci/djq526.CrossRefPubMed
11.
go back to reference Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, Dressler LG, Smith LV, Labbok MH, Geradts J, Bensen JT, Jackson S, Nyante S, Livasy C, Carey L, Earp HS, Perou CM: Epidemiology of basal-like breast cancer. Breast Cancer Res Treat. 2008, 109 (1): 123-139. 10.1007/s10549-007-9632-6.CrossRefPubMed Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, Dressler LG, Smith LV, Labbok MH, Geradts J, Bensen JT, Jackson S, Nyante S, Livasy C, Carey L, Earp HS, Perou CM: Epidemiology of basal-like breast cancer. Breast Cancer Res Treat. 2008, 109 (1): 123-139. 10.1007/s10549-007-9632-6.CrossRefPubMed
12.
go back to reference Gierach GL, Burke A, Anderson WF: Epidemiology of triple negative breast cancers. Breast Dis. 2010, 32 (1–2): 5-24.PubMed Gierach GL, Burke A, Anderson WF: Epidemiology of triple negative breast cancers. Breast Dis. 2010, 32 (1–2): 5-24.PubMed
13.
go back to reference Yasui Y, Potter JD: The shape of age-incidence curves of female breast cancer by hormone-receptor status. Cancer Causes Control. 1999, 10 (5): 431-437. 10.1023/A:1008970121595.CrossRefPubMed Yasui Y, Potter JD: The shape of age-incidence curves of female breast cancer by hormone-receptor status. Cancer Causes Control. 1999, 10 (5): 431-437. 10.1023/A:1008970121595.CrossRefPubMed
14.
go back to reference Phipps AI, Chlebowski RT, Prentice R, McTiernan A, Wactawski-Wende J, Kuller LH, Adams-Campbell LL, Lane D, Stefanick ML, Vitolins M, Kabat GC, Rohan TE, Li CI: Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer. J Natl Cancer Inst. 2011, 103 (6): 470-477. 10.1093/jnci/djr030.CrossRefPubMedPubMedCentral Phipps AI, Chlebowski RT, Prentice R, McTiernan A, Wactawski-Wende J, Kuller LH, Adams-Campbell LL, Lane D, Stefanick ML, Vitolins M, Kabat GC, Rohan TE, Li CI: Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer. J Natl Cancer Inst. 2011, 103 (6): 470-477. 10.1093/jnci/djr030.CrossRefPubMedPubMedCentral
15.
go back to reference Phipps AI, Malone KE, Porter PL, Daling JR, Li CI: Reproductive and hormonal risk factors for postmenopausal luminal, HER-2-overexpressing, and triple-negative breast cancer. Cancer. 2008, 113 (7): 1521-1526. 10.1002/cncr.23786.CrossRefPubMedPubMedCentral Phipps AI, Malone KE, Porter PL, Daling JR, Li CI: Reproductive and hormonal risk factors for postmenopausal luminal, HER-2-overexpressing, and triple-negative breast cancer. Cancer. 2008, 113 (7): 1521-1526. 10.1002/cncr.23786.CrossRefPubMedPubMedCentral
16.
go back to reference Riboli E, Kaaks R: The EPIC project: rationale and study design. European Prospective Investigation into Cancer and nutrition. Int J Epidemiol. 1997, 26 (1): S6-S14.CrossRefPubMed Riboli E, Kaaks R: The EPIC project: rationale and study design. European Prospective Investigation into Cancer and nutrition. Int J Epidemiol. 1997, 26 (1): S6-S14.CrossRefPubMed
17.
go back to reference Riboli E, Hunt KJ, Slimani N, Ferrari P, Norat T, Fahey M, Charrondiere UR, Hemon B, Casagrande C, Vignat J, Overvad K, Tjonneland A, Clavel-Chapelon F, Thiebaut A, Wahrendorf J, Boeing H, Trichopoulos D, Trichopoulou A, Vineis P, Palli D, Bueno-de-Mesquita HB, Peeters PH, Lund E, Engeset D, Gonzalez CA, Barricarte A, Berglund G, Hallmans G, Day NE, Key TJ, et al: European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr. 2002, 5 (6B): 1113-1124. 10.1079/PHN2002394.CrossRefPubMed Riboli E, Hunt KJ, Slimani N, Ferrari P, Norat T, Fahey M, Charrondiere UR, Hemon B, Casagrande C, Vignat J, Overvad K, Tjonneland A, Clavel-Chapelon F, Thiebaut A, Wahrendorf J, Boeing H, Trichopoulos D, Trichopoulou A, Vineis P, Palli D, Bueno-de-Mesquita HB, Peeters PH, Lund E, Engeset D, Gonzalez CA, Barricarte A, Berglund G, Hallmans G, Day NE, Key TJ, et al: European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr. 2002, 5 (6B): 1113-1124. 10.1079/PHN2002394.CrossRefPubMed
18.
go back to reference Onland-Moret NC, Peeters PH, van Gils CH, Clavel-Chapelon F, Key T, Tjonneland A, Trichopoulou A, Kaaks R, Manjer J, Panico S, Palli D, Tehard B, Stoikidou M, Bueno-de-Mesquita HB, Boeing H, Overvad K, Lenner P, Quiros JR, Chirlaque MD, Miller AB, Khaw KT, Riboli E: Age at menarche in relation to adult height: the EPIC study. Am J Epidemiol. 2005, 162 (7): 623-632. 10.1093/aje/kwi260.CrossRefPubMed Onland-Moret NC, Peeters PH, van Gils CH, Clavel-Chapelon F, Key T, Tjonneland A, Trichopoulou A, Kaaks R, Manjer J, Panico S, Palli D, Tehard B, Stoikidou M, Bueno-de-Mesquita HB, Boeing H, Overvad K, Lenner P, Quiros JR, Chirlaque MD, Miller AB, Khaw KT, Riboli E: Age at menarche in relation to adult height: the EPIC study. Am J Epidemiol. 2005, 162 (7): 623-632. 10.1093/aje/kwi260.CrossRefPubMed
19.
go back to reference Haftenberger M, Lahmann PH, Panico S, Gonzalez CA, Seidell JC, Boeing H, Giurdanella MC, Krogh V, Bueno-de-Mesquita HB, Peeters PH, Skeie G, Hjartaker A, Rodriguez M, Quiros JR, Berglund G, Janlert U, Khaw KT, Spencer EA, Overvad K, Tjonneland A, Clavel-Chapelon F, Tehard B, Miller AB, Klipstein-Grobusch K, Benetou V, Kiriazi G, Riboli E, Slimani N: Overweight, obesity and fat distribution in 50- to 64-year-old participants in the European Prospective Investigation into Cancer and Nutrition (EPIC). Public Health Nutr. 2002, 5 (6B): 1147-1162. 10.1079/PHN2002396.CrossRefPubMed Haftenberger M, Lahmann PH, Panico S, Gonzalez CA, Seidell JC, Boeing H, Giurdanella MC, Krogh V, Bueno-de-Mesquita HB, Peeters PH, Skeie G, Hjartaker A, Rodriguez M, Quiros JR, Berglund G, Janlert U, Khaw KT, Spencer EA, Overvad K, Tjonneland A, Clavel-Chapelon F, Tehard B, Miller AB, Klipstein-Grobusch K, Benetou V, Kiriazi G, Riboli E, Slimani N: Overweight, obesity and fat distribution in 50- to 64-year-old participants in the European Prospective Investigation into Cancer and Nutrition (EPIC). Public Health Nutr. 2002, 5 (6B): 1147-1162. 10.1079/PHN2002396.CrossRefPubMed
20.
go back to reference James RE, Lukanova A, Dossus L, Becker S, Rinaldi S, Tjonneland A, Olsen A, Overvad K, Mesrine S, Engel P, Clavel-Chapelon F, Chang-Claude J, Vrieling A, Boeing H, Schutze M, Trichopoulou A, Lagiou P, Trichopoulos D, Palli D, Krogh V, Panico S, Tumino R, Sacerdote C, Rodriguez L, Buckland G, Sanchez MJ, Amiano P, Ardanaz E, Bueno-de-Mesquita B, Ros MM, et al: Postmenopausal serum sex steroids and risk of hormone receptor-positive and -negative breast cancer: a nested case–control study. Cancer Prev Res. 2011, 4 (10): 1626-1635. 10.1158/1940-6207.CAPR-11-0090.CrossRef James RE, Lukanova A, Dossus L, Becker S, Rinaldi S, Tjonneland A, Olsen A, Overvad K, Mesrine S, Engel P, Clavel-Chapelon F, Chang-Claude J, Vrieling A, Boeing H, Schutze M, Trichopoulou A, Lagiou P, Trichopoulos D, Palli D, Krogh V, Panico S, Tumino R, Sacerdote C, Rodriguez L, Buckland G, Sanchez MJ, Amiano P, Ardanaz E, Bueno-de-Mesquita B, Ros MM, et al: Postmenopausal serum sex steroids and risk of hormone receptor-positive and -negative breast cancer: a nested case–control study. Cancer Prev Res. 2011, 4 (10): 1626-1635. 10.1158/1940-6207.CAPR-11-0090.CrossRef
21.
go back to reference Wareham NJ, Jakes RW, Rennie KL, Schuit J, Mitchell J, Hennings S, Day NE: Validity and repeatability of a simple index derived from the short physical activity questionnaire used in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Public Health Nutr. 2003, 6 (4): 407-413.CrossRefPubMed Wareham NJ, Jakes RW, Rennie KL, Schuit J, Mitchell J, Hennings S, Day NE: Validity and repeatability of a simple index derived from the short physical activity questionnaire used in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Public Health Nutr. 2003, 6 (4): 407-413.CrossRefPubMed
22.
go back to reference Heuch I, Albrektsen G, Kvale G: Modeling effects of age at and time since delivery on subsequent risk of cancer. Epidemiology. 1999, 10 (6): 739-746. 10.1097/00001648-199911000-00015.CrossRefPubMed Heuch I, Albrektsen G, Kvale G: Modeling effects of age at and time since delivery on subsequent risk of cancer. Epidemiology. 1999, 10 (6): 739-746. 10.1097/00001648-199911000-00015.CrossRefPubMed
23.
go back to reference Lunn M, McNeil D: Applying Cox regression to competing risks. Biometrics. 1995, 51 (2): 524-532. 10.2307/2532940.CrossRefPubMed Lunn M, McNeil D: Applying Cox regression to competing risks. Biometrics. 1995, 51 (2): 524-532. 10.2307/2532940.CrossRefPubMed
24.
go back to reference Ritte R, Lukanova A, Berrino F, Dossus L, Tjonneland A, Olsen A, Overvad TF, Overvad K, Clavel-Chapelon F, Fournier A, Fagherazzi G, Rohrmann S, Teucher B, Boeing H, Aleksandrova K, Trichopoulou A, Lagiou P, Trichopoulos D, Palli D, Sieri S, Panico S, Tumino R, Vineis P, Quiros JR, Buckland G, Sanchez MJ, Amiano P, Chirlaque MD, Ardanaz E, Sund M, et al: Adiposity, hormone replacement therapy use and breast cancer risk by age and hormone receptor status: a large prospective cohort study. Breast Cancer Res. 2012, 14 (3): R76-10.1186/bcr3186.CrossRefPubMedPubMedCentral Ritte R, Lukanova A, Berrino F, Dossus L, Tjonneland A, Olsen A, Overvad TF, Overvad K, Clavel-Chapelon F, Fournier A, Fagherazzi G, Rohrmann S, Teucher B, Boeing H, Aleksandrova K, Trichopoulou A, Lagiou P, Trichopoulos D, Palli D, Sieri S, Panico S, Tumino R, Vineis P, Quiros JR, Buckland G, Sanchez MJ, Amiano P, Chirlaque MD, Ardanaz E, Sund M, et al: Adiposity, hormone replacement therapy use and breast cancer risk by age and hormone receptor status: a large prospective cohort study. Breast Cancer Res. 2012, 14 (3): R76-10.1186/bcr3186.CrossRefPubMedPubMedCentral
25.
go back to reference Setiawan VW, Monroe KR, Wilkens LR, Kolonel LN, Pike MC, Henderson BE: Breast cancer risk factors defined by estrogen and progesterone receptor status: the multiethnic cohort study. Am J Epidemiol. 2009, 169 (10): 1251-1259. 10.1093/aje/kwp036.CrossRefPubMedPubMedCentral Setiawan VW, Monroe KR, Wilkens LR, Kolonel LN, Pike MC, Henderson BE: Breast cancer risk factors defined by estrogen and progesterone receptor status: the multiethnic cohort study. Am J Epidemiol. 2009, 169 (10): 1251-1259. 10.1093/aje/kwp036.CrossRefPubMedPubMedCentral
26.
go back to reference Hankinson SE, Tamimi R, Hunter D: Breast cancer. Textbook of Cancer Epidemiology. Edited by: Adami H, Hunter D, Trichopoulos D. 2008, Oxford: Oxford University Press, 403-445. 2CrossRef Hankinson SE, Tamimi R, Hunter D: Breast cancer. Textbook of Cancer Epidemiology. Edited by: Adami H, Hunter D, Trichopoulos D. 2008, Oxford: Oxford University Press, 403-445. 2CrossRef
27.
go back to reference Ritte R, Lukanova A, Tjonneland A, Olsen A, Overvad K, Mesrine S, Fagherazzi G, Dossus L, Teucher B, Steindorf K, Boeing H, Aleksandrova K, Trichopoulou A, Lagiou P, Trichopoulos D, Palli D, Grioni S, Mattiello A, Tumino R, Sacerdote C, Quiros JR, Buckland G, Molina-Montes E, Chirlaque MD, Ardanaz E, Amiano P, Bueno-de-Mesquita B, Van DF, Van Gils CH, Peeters PH, et al: Height, age at menarche and risk of hormone receptor-positive and -negative breast cancer: a cohort study. Int J Cancer J Int du cancer. 2013, 132 (11): 2619-2629. 10.1002/ijc.27913.CrossRef Ritte R, Lukanova A, Tjonneland A, Olsen A, Overvad K, Mesrine S, Fagherazzi G, Dossus L, Teucher B, Steindorf K, Boeing H, Aleksandrova K, Trichopoulou A, Lagiou P, Trichopoulos D, Palli D, Grioni S, Mattiello A, Tumino R, Sacerdote C, Quiros JR, Buckland G, Molina-Montes E, Chirlaque MD, Ardanaz E, Amiano P, Bueno-de-Mesquita B, Van DF, Van Gils CH, Peeters PH, et al: Height, age at menarche and risk of hormone receptor-positive and -negative breast cancer: a cohort study. Int J Cancer J Int du cancer. 2013, 132 (11): 2619-2629. 10.1002/ijc.27913.CrossRef
28.
go back to reference Apter D, Reinila M, Vihko R: Some endocrine characteristics of early menarche, a risk factor for breast cancer, are preserved into adulthood. Int J Cancer. 1989, 44 (5): 783-787. 10.1002/ijc.2910440506.CrossRefPubMed Apter D, Reinila M, Vihko R: Some endocrine characteristics of early menarche, a risk factor for breast cancer, are preserved into adulthood. Int J Cancer. 1989, 44 (5): 783-787. 10.1002/ijc.2910440506.CrossRefPubMed
29.
go back to reference Dietel M, Lewis MA, Shapiro S: Hormone replacement therapy: pathobiological aspects of hormone-sensitive cancers in women relevant to epidemiological studies on HRT: a mini-review. Hum Reprod. 2005, 20 (8): 2052-2060. 10.1093/humrep/dei043.CrossRefPubMed Dietel M, Lewis MA, Shapiro S: Hormone replacement therapy: pathobiological aspects of hormone-sensitive cancers in women relevant to epidemiological studies on HRT: a mini-review. Hum Reprod. 2005, 20 (8): 2052-2060. 10.1093/humrep/dei043.CrossRefPubMed
30.
go back to reference Allred DC, Brown P, Medina D: The origins of estrogen receptor alpha-positive and estrogen receptor alpha-negative human breast cancer. Breast Cancer Res. 2004, 6 (6): 240-245. 10.1186/bcr938.CrossRefPubMedPubMedCentral Allred DC, Brown P, Medina D: The origins of estrogen receptor alpha-positive and estrogen receptor alpha-negative human breast cancer. Breast Cancer Res. 2004, 6 (6): 240-245. 10.1186/bcr938.CrossRefPubMedPubMedCentral
31.
go back to reference Asselin-Labat ML, Vaillant F, Sheridan JM, Pal B, Wu D, Simpson ER, Yasuda H, Smyth GK, Martin TJ, Lindeman GJ, Visvader JE: Control of mammary stem cell function by steroid hormone signalling. Nature. 2010, 465 (7299): 798-802. 10.1038/nature09027.CrossRefPubMed Asselin-Labat ML, Vaillant F, Sheridan JM, Pal B, Wu D, Simpson ER, Yasuda H, Smyth GK, Martin TJ, Lindeman GJ, Visvader JE: Control of mammary stem cell function by steroid hormone signalling. Nature. 2010, 465 (7299): 798-802. 10.1038/nature09027.CrossRefPubMed
32.
go back to reference Russo IH, Russo J: Pregnancy-induced changes in breast cancer risk. J Mammary Gland Biol Neoplasia. 2011, 16 (3): 221-233. 10.1007/s10911-011-9228-y.CrossRefPubMed Russo IH, Russo J: Pregnancy-induced changes in breast cancer risk. J Mammary Gland Biol Neoplasia. 2011, 16 (3): 221-233. 10.1007/s10911-011-9228-y.CrossRefPubMed
33.
go back to reference Ma H, Bernstein L, Ross RK, Ursin G: Hormone-related risk factors for breast cancer in women under age 50 years by estrogen and progesterone receptor status: results from a case–control and a case-case comparison. Breast Cancer Res. 2006, 8 (4): R39-10.1186/bcr1514.CrossRefPubMedPubMedCentral Ma H, Bernstein L, Ross RK, Ursin G: Hormone-related risk factors for breast cancer in women under age 50 years by estrogen and progesterone receptor status: results from a case–control and a case-case comparison. Breast Cancer Res. 2006, 8 (4): R39-10.1186/bcr1514.CrossRefPubMedPubMedCentral
34.
go back to reference Dolle JM, Daling JR, White E, Brinton LA, Doody DR, Porter PL, Malone KE: Risk factors for triple-negative breast cancer in women under the age of 45 years. Cancer Epidemiol Biomarkers Prev. 2009, 18 (4): 1157-1166. 10.1158/1055-9965.EPI-08-1005.CrossRefPubMedPubMedCentral Dolle JM, Daling JR, White E, Brinton LA, Doody DR, Porter PL, Malone KE: Risk factors for triple-negative breast cancer in women under the age of 45 years. Cancer Epidemiol Biomarkers Prev. 2009, 18 (4): 1157-1166. 10.1158/1055-9965.EPI-08-1005.CrossRefPubMedPubMedCentral
35.
go back to reference Althuis MD, Brogan DD, Coates RJ, Daling JR, Gammon MD, Malone KE, Schoenberg JB, Brinton LA: Breast cancers among very young premenopausal women (United States). Cancer Causes Control. 2003, 14 (2): 151-160. 10.1023/A:1023006000760.CrossRefPubMed Althuis MD, Brogan DD, Coates RJ, Daling JR, Gammon MD, Malone KE, Schoenberg JB, Brinton LA: Breast cancers among very young premenopausal women (United States). Cancer Causes Control. 2003, 14 (2): 151-160. 10.1023/A:1023006000760.CrossRefPubMed
36.
go back to reference Sweeney C, Giuliano AR, Baumgartner KB, Byers T, Herrick JS, Edwards SL, Slattery ML: Oral, injected and implanted contraceptives and breast cancer risk among U.S. Hispanic and non-Hispanic white women. Int J Cancer. 2007, 121 (11): 2517-2523. 10.1002/ijc.22970.CrossRefPubMed Sweeney C, Giuliano AR, Baumgartner KB, Byers T, Herrick JS, Edwards SL, Slattery ML: Oral, injected and implanted contraceptives and breast cancer risk among U.S. Hispanic and non-Hispanic white women. Int J Cancer. 2007, 121 (11): 2517-2523. 10.1002/ijc.22970.CrossRefPubMed
37.
go back to reference Rosenberg L, Boggs DA, Wise LA, Adams-Campbell LL, Palmer JR: Oral contraceptive use and estrogen/progesterone receptor-negative breast cancer among African American women. Cancer Epidemiol Biomarkers Prev. 2010, 19 (8): 2073-2079. 10.1158/1055-9965.EPI-10-0428.CrossRefPubMedPubMedCentral Rosenberg L, Boggs DA, Wise LA, Adams-Campbell LL, Palmer JR: Oral contraceptive use and estrogen/progesterone receptor-negative breast cancer among African American women. Cancer Epidemiol Biomarkers Prev. 2010, 19 (8): 2073-2079. 10.1158/1055-9965.EPI-10-0428.CrossRefPubMedPubMedCentral
38.
go back to reference Magne N, Toillon RA, Castadot P, Ramaioli A, Namer M: Different clinical impact of estradiol receptor determination according to the analytical method: a study on 1940 breast cancer patients over a period of 16 consecutive years. Breast Cancer Res Treat. 2006, 95 (2): 179-184. 10.1007/s10549-005-9065-z.CrossRefPubMed Magne N, Toillon RA, Castadot P, Ramaioli A, Namer M: Different clinical impact of estradiol receptor determination according to the analytical method: a study on 1940 breast cancer patients over a period of 16 consecutive years. Breast Cancer Res Treat. 2006, 95 (2): 179-184. 10.1007/s10549-005-9065-z.CrossRefPubMed
39.
go back to reference Chebil G, Bendahl PO, Idvall I, Ferno M: Comparison of immunohistochemical and biochemical assay of steroid receptors in primary breast cancer–clinical associations and reasons for discrepancies. Acta Oncol. 2003, 42 (7): 719-725. 10.1080/02841860310004724.CrossRefPubMed Chebil G, Bendahl PO, Idvall I, Ferno M: Comparison of immunohistochemical and biochemical assay of steroid receptors in primary breast cancer–clinical associations and reasons for discrepancies. Acta Oncol. 2003, 42 (7): 719-725. 10.1080/02841860310004724.CrossRefPubMed
40.
go back to reference Welsh AW, Moeder CB, Kumar S, Gershkovich P, Alarid ET, Harigopal M, Haffty BG, Rimm DL: Standardization of estrogen receptor measurement in breast cancer suggests false-negative results are a function of threshold intensity rather than percentage of positive cells. J Clin Oncol. 2011, 29 (22): 2978-2984. 10.1200/JCO.2010.32.9706.CrossRefPubMedPubMedCentral Welsh AW, Moeder CB, Kumar S, Gershkovich P, Alarid ET, Harigopal M, Haffty BG, Rimm DL: Standardization of estrogen receptor measurement in breast cancer suggests false-negative results are a function of threshold intensity rather than percentage of positive cells. J Clin Oncol. 2011, 29 (22): 2978-2984. 10.1200/JCO.2010.32.9706.CrossRefPubMedPubMedCentral
41.
go back to reference Hede K: Breast cancer testing scandal shines spotlight on black box of clinical laboratory testing. J Natl Cancer Inst. 2008, 100 (12): 836-837. 10.1093/jnci/djn200.CrossRefPubMed Hede K: Breast cancer testing scandal shines spotlight on black box of clinical laboratory testing. J Natl Cancer Inst. 2008, 100 (12): 836-837. 10.1093/jnci/djn200.CrossRefPubMed
42.
go back to reference Chu KC, Anderson WF, Fritz A, Ries LA, Brawley OW: Frequency distributions of breast cancer characteristics classified by estrogen receptor and progesterone receptor status for eight racial/ethnic groups. Cancer. 2001, 92 (1): 37-45. 10.1002/1097-0142(20010701)92:1<37::AID-CNCR1289>3.0.CO;2-F.CrossRefPubMed Chu KC, Anderson WF, Fritz A, Ries LA, Brawley OW: Frequency distributions of breast cancer characteristics classified by estrogen receptor and progesterone receptor status for eight racial/ethnic groups. Cancer. 2001, 92 (1): 37-45. 10.1002/1097-0142(20010701)92:1<37::AID-CNCR1289>3.0.CO;2-F.CrossRefPubMed
Metadata
Title
Reproductive factors and risk of hormone receptor positive and negative breast cancer: a cohort study
Authors
Rebecca Ritte
Kaja Tikk
Annekatrin Lukanova
Anne Tjønneland
Anja Olsen
Kim Overvad
Laure Dossus
Agnès Fournier
Françoise Clavel-Chapelon
Verena Grote
Heiner Boeing
Krasimira Aleksandrova
Antonia Trichopoulou
Pagona Lagiou
Dimitrios Trichopoulos
Domenico Palli
Franco Berrino
Amalia Mattiello
Rosario Tumino
Carlotta Sacerdote
José Ramón Quirós
Genevieve Buckland
Esther Molina-Montes
María-Dolores Chirlaque
Eva Ardanaz
Pilar Amiano
H Bas Bueno-de-Mesquita
Carla H van Gils
Petra HM Peeters
Nick Wareham
Kay-Tee Khaw
Timothy J Key
Ruth C Travis
Elisabete Weiderpass
Vanessa Dumeaux
Eliv Lund
Malin Sund
Anne Andersson
Isabelle Romieu
Sabina Rinaldi
Paulo Vineis
Melissa A Merritt
Elio Riboli
Rudolf Kaaks
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2013
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-13-584

Other articles of this Issue 1/2013

BMC Cancer 1/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine